Celgene Says FDA Approves Otezla for Oral Ulcers in Behcet's Disease
July 19 2019 - 2:47PM
Dow Jones News
By Michael Dabaie
Celgene Corp. (CELG) said the U.S. Food and Drug Administration
approved Otezla 30 mg twice daily for adults with oral ulcers
associated with Behcet's Disease.
Behcet's Disease is a rare, chronic, multisystem inflammatory
disease that is difficult to treat, Celgene said. Otezla reduced
the number and pain of oral ulcers in a 12-week placebo-controlled
Phase 3 study.
Otezla is now approved for three indications in the U.S.,
including the treatment of patients with moderate to severe plaque
psoriasis, the company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 19, 2019 14:32 ET (18:32 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2023 to Sep 2024